Solid Biosciences (SLDB) Total Non-Current Liabilities (2018 - 2024)
Solid Biosciences' Total Non-Current Liabilities history spans 5 years, with the latest figure at $22.0 million for Q3 2024.
- For Q3 2024, Total Non-Current Liabilities changed N/A year-over-year to $22.0 million; the TTM value through Sep 2024 reached $22.0 million, changed N/A, while the annual FY2023 figure was $23.9 million, 50.63% down from the prior year.
- Total Non-Current Liabilities for Q3 2024 was $22.0 million at Solid Biosciences, down from $23.0 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $48.5 million in Q4 2022 and bottomed at $22.0 million in Q3 2024.
- The 4-year median for Total Non-Current Liabilities is $23.9 million (2023), against an average of $31.0 million.
- The largest YoY upside for Total Non-Current Liabilities was 50.63% in 2023 against a maximum downside of 50.63% in 2023.
- A 4-year view of Total Non-Current Liabilities shows it stood at $37.8 million in 2020, then grew by 28.34% to $48.5 million in 2022, then tumbled by 50.63% to $23.9 million in 2023, then decreased by 8.32% to $22.0 million in 2024.
- Per Business Quant, the three most recent readings for SLDB's Total Non-Current Liabilities are $22.0 million (Q3 2024), $23.0 million (Q2 2024), and $23.9 million (Q4 2023).